Dyskeratosis Congenita Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting dyskeratosis congenita clinical trials across 1 country. Studies span Phase 1, Phase 2. Top locations include Memphis, Tennessee, United States, Bethesda, Maryland, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Dyskeratosis Congenita Trials at a Glance

7 actively recruiting trials for dyskeratosis congenita are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Memphis, Bethesda, and Boston. Lead sponsors running dyskeratosis congenita studies include St. Jude Children's Research Hospital, Children's Hospital Medical Center, Cincinnati, and Masonic Cancer Center, University of Minnesota.

Browse dyskeratosis congenita trials by phase

Treatments under study

About Dyskeratosis Congenita Clinical Trials

Looking for clinical trials for Dyskeratosis Congenita? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dyskeratosis Congenita trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dyskeratosis Congenita clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Cancer in Inherited Bone Marrow Failure Syndromes

Diamond-Blackfan AnemiaDyskeratosis CongenitaFanconi Anemia+2 more
National Cancer Institute (NCI)4,000 enrolled2 locationsNCT00027274
Recruiting

Investigation of the Genetics of Hematologic Diseases

Diamond-Blackfan AnemiaDyskeratosis CongenitaFanconi Anemia+10 more
St. Jude Children's Research Hospital1,716 enrolled1 locationNCT02720679
Recruiting
Phase 1

Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)

Dyskeratosis CongenitaTelomere Disease
Children's Hospital Medical Center, Cincinnati12 enrolled1 locationNCT07628972
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 1

Nucleoside Therapy in Patients With Telomere Biology Disorders

Dyskeratosis CongenitaTelomere Biology DisordersHoyeraal-Hreidarsson Syndrome+4 more
Suneet Agarwal36 enrolled1 locationNCT06817590
Recruiting
Phase 2

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Dyskeratosis CongenitaFanconi AnemiaMyelodysplastic Syndromes+5 more
Masonic Cancer Center, University of Minnesota48 enrolled1 locationNCT03579875
Recruiting
Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Dyskeratosis CongenitaFanconi AnemiaBone Marrow Failure+7 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins27 enrolled1 locationNCT04232085